|
KURA | Kura Oncology, Inc. |
|
|
KURA | Kura Oncology, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.37 |
| Leverage | 62.65% |
| Market Cap | $ 652.5m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -216.5m |
| Margin | -244.36% |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.